GGH2 Antibody
Description
Introduction to GH2 Antibody
GH2 Antibodies are immunoreagents targeting Growth Hormone 2, a member of the somatotropin/prolactin family. GH2 is critical in growth regulation, primarily by stimulating insulin-like growth factor 1 (IGF-1) secretion in the liver and promoting myoblast differentiation . These antibodies are utilized in research and clinical applications, including cancer therapeutics and growth disorder studies.
Mechanisms of Action
GH2 Antibodies mediate biological effects through multiple pathways:
-
Growth Regulation: Binds GH2 to stimulate IGF-1 secretion, enhancing protein synthesis and cellular proliferation .
-
Immune Effector Functions:
-
Therapeutic Targeting: Engineered IgG2 antibodies exhibit FcγR-independent agonism due to unique hinge disulfide configurations, enhancing tumor cell killing .
Research Applications
GH2 Antibodies are pivotal in diverse experimental and clinical settings:
Table 1: Key Research Applications
Cancer Therapy
-
EGFR Targeting: IgG2 GH2 antibodies (e.g., panitumumab) demonstrate potent ADCC and CDC against EGFR+ tumors, even at low antigen density .
-
HER2+ Gastric Cancer: GH2-75 and GH2-61 ADCs show efficacy in xenograft models, with drug-antibody ratios (DAR) of 2 maintaining binding affinity .
Autoimmune and Infectious Diseases
-
SARS-CoV-2 Neutralization: Hexavalent GH2-derived heavy-chain-only antibodies neutralize Omicron variants by avidity engineering .
Table 2: Standard Protocols for GH2 Antibody Use
| Application | Dilution | Antigen Retrieval |
|---|---|---|
| Western Blot (WB) | 1:500–1:1000 | Not required |
| Immunohistochemistry | 1:20–1:200 | TE buffer (pH 9.0) or citrate buffer (pH 6.0) |
Storage: -20°C in PBS with 0.02% sodium azide and 50% glycerol .
Table 3: IgG2 vs. IgG1 Functional Properties
| Property | IgG2 | IgG1 |
|---|---|---|
| FcγR Dependence | Independent (hinge disulfide configuration) | Dependent |
| ADCC Efficiency | Higher in low EGFR/CD47 expression | Moderate |
| Clinical Use | Panitumumab (EGFR) | Trastuzumab (HER2) |
Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
FAQs for GH2 Antibody Research (Note: Presumed typographical error; "GGH2" interpreted as GH2 based on literature context)
Advanced Research Questions
How to resolve discrepancies in GH2 antibody performance across cancer models?
Case Study: In HER2⁺ gastric cancer xenografts (N87 model), GH2-75 and GH2-61 antibodies showed variable tumor uptake compared to trastuzumab .
| Antibody | Tumor Uptake (%ID/g) | Off-Target Binding (Liver %ID/g) | Citation |
|---|---|---|---|
| GH2-75 | 12.3 ± 1.8 | 4.1 ± 0.9 | |
| Trastuzumab | 8.7 ± 1.2 | 2.3 ± 0.5 |
Resolution Strategy:
-
Perform in vivo biodistribution with dual-isotope labeling (e.g., ¹¹¹In for GH2, ⁶⁸Ga for trastuzumab) .
-
Analyze HER2 density via flow cytometry (MFI >10⁴ required for GH2-75 efficacy) .
Can GH2 antibody engineering improve neutralization breadth against viral variants?
Engineering Approach:
-
Valency Optimization: Hexavalent GH2-based heavy-chain-only antibodies increased SARS-CoV-2 pseudovirus neutralization by 160-fold vs. bivalent forms .
-
Epitope Binning: Use BLI competition assays (Figure 1E in ) to avoid steric hindrance in multispecific designs.
How to leverage protein language models for GH2 affinity maturation?
Workflow:
-
Screen top 20 predicted mutations across two evolution rounds .
-
Validate via SPR (KD improvement up to 7-fold observed for anti-SARS-CoV-2 GH2 variants) .
Data Contradiction Analysis
Why do some studies report GH2 antibody agonism while others do not?
Key Variables:
-
Isotype Dependency: Human IgG2 (h2) confers FcγR-independent agonism via hinge disulfide constraints .
-
Structural Confirmation: Locked h2B subfraction (Cys²²⁶–Cys²²⁹ bonds) increases CD40 activation by 4.8-fold vs. h1 .
| Isotype | Agonistic Activity (EC₅₀, nM) | FcγR Dependency |
|---|---|---|
| h2 | 0.48 ± 0.12 | No |
| h1 | 2.31 ± 0.45 | Yes |
Resolution: Precisely characterize antibody hinge configuration via non-reducing SDS-PAGE before functional assays .
